aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
March 14, 2024 16:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
February 21, 2024 08:00 ET
|
aTyr Pharma, Inc.
Tyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
January 29, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to present posters on the importance of Neuropilin-2 in immune regulation at the Keystone Symposia on Myeloid Cell Diversity.
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
January 18, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).
aTyr Pharma to Present at November Investor Conferences
November 01, 2023 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma announces that it will present at two investor conferences in November 2023.
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
September 11, 2023 08:00 ET
|
aTyr Pharma, Inc.
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 24, 2023 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application
March 01, 2023 08:00 ET
|
aTyr Pharma, Inc.
Proof-of-Concept study in SSc-ILD expected to begin in 2023. Efzofitimod has been granted U.S. FDA orphan drug designation for SSc and Fast Track designation for SSc-ILD. SAN DIEGO, March 01, 2023 ...
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
November 09, 2022 08:00 ET
|
aTyr Pharma, Inc.
First therapy in sarcoidosis to reduce steroid burden while demonstrating improvements in key physiologic and quality of life measures. Global pivotal Phase 3 EFZO-FIT™ study currently enrolling. ...
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
October 11, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines...